VELETI II Study
Sealing Moderate Coronary Saphenous Vein Graft Lesions with Paclitaxel-eluting stents as a new approach to maintaining vein graft patency and reducing cardiac events.
Or Vein Graft Lesions Treated with the Taxus Stent. An IVUS Study.
Primary Investigator: Dr. Sanjit Jolly
Contact Person: Dr. Sanjit Jolly 905-527-4322 ext 40309
Summary of Protocol:
The VELETI II Study is being done to determine the success of stenting moderate blockages in Saphenous Vein Grafts for patients who have had a prior Coronary Artery Bypass Graft (CABG). Patients having moderate blockages of these vessels will be randomized to receive either a Paclitaxel-eluting stent or standard medical therapy. Paclitaxel is a medication which is released over time and helps to prevent re-narrowing of the blood vessel. The VELETI II Study is important as it will provide valuable information regarding most effective care for patients in the future.
This study is currently recruiting.